NEW YORK (GenomeWeb News) – Cellectis today announced that a French court has dismissed a lawsuit filed by Taconic Artemis and Taconic Farms against Cellectis after it terminated a sublicensing contract related to homologous recombination patents.
The decision, rendered by the third chamber of the Paris Tribunal de Grande Instance on June 29, means that Taconic and Taconic Artemis' rights to create and sell transgenic animal models under patents held by Cellectis ended on Aug. 6, 2008 when Cellectis terminated a sublicensing agreement with Taconic, after claiming Taconic had breached the contract's terms.
In a statement, Cellectis added that the court's decision "confirms that the products sold by Taconic, namely transgenic animals constructed using the teaching of the patents, could not and still cannot be bred by a third party."
Cellectis will receive financial compensation for damages and losses, the company said, without elaborating.
Cellectis had granted Taconic and Taconic Farms a sublicense to its patents covering certain uses of homologous recombination to perform targeted modifications in the genomic DNA of eukaryotic cells. In August 2008, Cellectis terminated the agreement. Four months later, Taconic and Taconic Farms sued Cellectis.
Taconic Artemis was a subsidiary of Taconic Farms, which now operates under the name Taconic.
At publication time of this article, Taconic did not reply to a request for comment.